The tumor distance to the main hepatic vessels is a predictor of recurrence-free survival and overall survival in hepatocellular cancer

Langenbeck s Archives of Surgery, Journal Year: 2025, Volume and Issue: 410(1)

Published: Jan. 9, 2025

Abstract Introduction The impact of the distance tumor from main hepatic vessels (DTV), such as Glissonean pedicle or veins, on oncological outcomes for Hepatocellular carcinoma (HCC) patients is relatively understudied. Therefore, objective this study was to explore correlation between DTV and survival in with HCC after curative resection. Methods Consecutive who underwent curative-intent liver surgery April 2018 May 2023 were identified a prospective database. Univariate multivariate Cox regression analysis performed identify independent predictors recurrence-free (RFS). A ROC-curve used find optimal cut-off value DTV. According estimated value, divided into 2 subgroups, then using Kaplan-Meier curve, RFS overall (OS) compared subgroups. Results In univariate analysis, DTV, size, resection margins, microvascular invasion (MVI) grading associated RFS. MVI confirmed ROC-analysis cutoff 20 mm. Patients < mm had larger size more advanced histopathological grading. There no difference presence both groups, while significantly experienced recurrence hepatectomy group. Accordingly, shorter median OS. Conclusion promising predictor OS HCC.

Language: Английский

Integrating single-cell RNA-Seq and bulk RNA-Seq data to explore the key role of fatty acid metabolism in hepatocellular carcinoma

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 15, 2025

Hepatocellular carcinoma (HCC) is a predominant cause of cancer-related mortality globally, noted for its propensity towards late-stage diagnosis and scarcity effective treatment modalities. The process metabolic reprogramming, with specific emphasis on lipid metabolism, instrumental in the progression HCC. Nevertheless, precise mechanisms through which metabolism impacts HCC viability as therapeutic target have yet to be fully elucidated. In current investigation, single-cell RNA sequencing conjunction weighted gene co-expression network analysis (WGCNA) was utilized delineate metabolism-related genes correlated prognostic outcomes hepatocellular (HCC). Data procurement encompassed transcriptomic clinical datasets from patients, sourced Cancer Genome Atlas (TCGA) Gene Expression Omnibus (GEO) repositories. Subsequent this, consensus clustering implemented stratify patients into distinct subgroups, contingent upon expression patterns genes. Further analytical procedures involved functional enrichment analysis, evaluation immune infiltration, examination mutation landscape.PTGES3 identified pivotal associated metabolism. identification, cellular communication employed assess immunological attributes PTGES3 within tumor microenvironment. role further corroborated molecular docking simulations vitro experimental assays. We 27 18 exhibited significant correlation overall survival patients. emerged central gene, demonstrating robust association cell infiltration unfavorable prognosis. Cellular revealed that exhibits highest intensity T cells, modulating microenvironment by potentiating FN1/CD44 + MDK/NCL signaling pathway. Elevated linked immunosuppressive cascades, diminished responsiveness immunotherapy, inferior outcomes. Molecular indicated etoposide, methotrexate, doxorubicin could effectively bind PTGES3. experiments confirmed knockdown significantly impaired proliferation, invasion, migration cells. This study highlights identifies potential biomarker target. These findings offer new insights development targeted therapies HCC, particularly high expression.

Language: Английский

Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: June 10, 2024

Background: Unresectable hepatocellular carcinoma (uHCC) patients with Child-Pugh grade B have limited treatment options and poor outcomes. Methods: Patients uHCC Child-pugh who received lenvatinib plus PD-1 inhibitors or sorafenib at one of three centers were retrospectively reviewed. These divided into two subgroups: B7 (Group A, n =106) another B/9 B, = 73). Overall survival (OS) was defined as the primary endpoint. Secondary endpoints included time to progression (TTP), objective response rate (ORR), safety. Prognostic factors evaluated using multivariate Cox proportional hazards models, while nomograms constructed predict 12-month survival. Results: Between December 31, 2020 March 30, 2023, a total 179 enrolled. The disease control rates in Child–pugh groups A 26.0% 76.7%, 33.0% 83.0%, respectively. There no difference median TTP (6.3 vs. 7.8 months, P 0.28) OS (14.0 17.8months, 0.20) between Group A. However, safety profiles comparable groups, B8/9 had significantly higher frequency dose reductions discontinuations (P 0.04 < 0.001), compared those B7. According results analysis，we nomogram rates，considering tumor size, BCLC stage, , drug resistance. nomogram-related receiver operating characteristics (ROC) curves indicated that area under curve (AUC) values 0.752. Furthermore, calibration revealed good agreement real measurements predictions. Conclusions: combination multi-kinase (lenvatinib sorafenib) safe, well-tolerated, especially it can also benefit B8/9.

Language: Английский